|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
45,560,000 |
Market
Cap: |
12.06(M) |
Last
Volume: |
1,167,076 |
Avg
Vol: |
536,427 |
52
Week Range: |
$0.2646 - $0.2646 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Protalix BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system. Co.'s proprietary ProCellEx platform is being used to manufacture its marketed product, Elelyso®, for the treatment of Gaucher disease. Co. is also developing, via ProCellEx, a pipeline of products. Co.'s clinical development program for pegunigalsidase alfa, or PRX-102, for the potential treatment of Fabry disease. In addition, Co. is developing uricase, or PRX-115, for the treatment of refractory gout.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
64,516 |
174,516 |
Total Buy Value |
$0 |
$0 |
$90,484 |
$246,299 |
Total People Bought |
0 |
0 |
1 |
2 |
Total Buy Transactions |
0 |
0 |
1 |
2 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bio-Cell Ltd |
10% Owner |
|
2014-09-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(8,556,371) |
1,509,948 |
|
- |
|
Bronfeld Zeev |
Director |
|
2014-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,838,109 |
1,838,109 |
|
- |
|
Bronfeld Zeev |
Director |
|
2014-09-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(8,556,371) |
1,509,948 |
|
- |
|
Bio-Cell Ltd |
10% Owner |
|
2014-08-13 |
4 |
S |
$2.47 |
$10,868,000 |
I/I |
(4,400,000) |
10,066,319 |
|
- |
|
Bronfeld Zeev |
Director |
|
2014-08-13 |
4 |
S |
$2.47 |
$10,868,000 |
I/I |
(4,400,000) |
10,066,319 |
|
- |
|
Akirov Alfred |
Director |
|
2013-08-15 |
4 |
S |
$5.07 |
$11,813 |
I/I |
(2,330) |
4,915,383 |
|
- |
|
Akirov Alfred |
Director |
|
2013-08-14 |
4 |
S |
$5.05 |
$555,750 |
I/I |
(110,000) |
4,917,713 |
|
- |
|
Akirov Alfred |
Director |
|
2013-03-12 |
4 |
S |
$5.70 |
$57,000 |
I/I |
(10,000) |
5,027,713 |
|
- |
|
Akirov Alfred |
Director |
|
2013-03-11 |
4 |
S |
$5.71 |
$104,737 |
I/I |
(18,300) |
5,037,711 |
|
- |
|
Akirov Alfred |
Director |
|
2013-03-08 |
4 |
S |
$5.82 |
$99,068 |
I/I |
(16,898) |
5,056,013 |
|
- |
|
Akirov Alfred |
Director |
|
2013-03-07 |
4 |
S |
$5.71 |
$48,233 |
I/I |
(8,435) |
5,072,911 |
|
- |
|
Akirov Alfred |
Director |
|
2013-03-06 |
4 |
S |
$5.68 |
$26,737 |
I/I |
(4,700) |
5,081,346 |
|
- |
|
Almon Einat Brill |
SVP, Product Development |
|
2012-07-16 |
4 |
A |
$0.00 |
$0 |
I/I |
185,000 |
185,000 |
|
- |
|
Lauterbach Sandra Leigh |
VP, Sales & Commercial Affairs |
|
2012-07-16 |
4 |
A |
$0.00 |
$0 |
I/I |
20,000 |
20,000 |
|
- |
|
Yossi Maimon |
Vice President & CFO |
|
2012-07-16 |
4 |
A |
$0.00 |
$0 |
I/I |
185,000 |
185,000 |
|
- |
|
Palash Tzvi |
Chief Operating Officer |
|
2012-07-16 |
4 |
A |
$0.00 |
$0 |
I/I |
102,000 |
102,000 |
|
- |
|
Shaaltiel Yoseph |
Executive VP, R&D |
|
2012-07-16 |
4 |
A |
$0.00 |
$0 |
I/I |
210,000 |
210,000 |
|
- |
|
Aviezer David |
President & CEO |
|
2012-07-16 |
4 |
A |
$0.00 |
$0 |
I/I |
418,000 |
418,000 |
|
- |
|
Aviezer David |
President & CEO |
|
2012-05-02 |
4 |
AS |
$7.13 |
$3,208,500 |
I/I |
(450,000) |
0 |
|
- |
|
Aviezer David |
President & CEO |
|
2012-05-02 |
4 |
OE |
$0.12 |
$159,421 |
I/I |
450,000 |
450,000 |
|
- |
|
Yossi Maimon |
VP, Chief Financial Officer |
|
2012-05-02 |
4 |
AS |
$7.13 |
$898,123 |
I/I |
(125,964) |
0 |
|
- |
|
Yossi Maimon |
VP, Chief Financial Officer |
|
2012-05-02 |
4 |
OE |
$0.97 |
$206,337 |
I/I |
125,964 |
125,964 |
|
- |
|
Yossi Maimon |
VP, Chief Financial Officer |
|
2010-10-07 |
4 |
D |
$9.73 |
$75,592 |
I/I |
(7,769) |
0 |
|
- |
|
Yossi Maimon |
VP, Chief Financial Officer |
|
2010-10-07 |
4 |
OE |
$0.97 |
$75,591 |
I/I |
77,769 |
0 |
|
- |
|
Yossi Maimon |
VP, Chief Financial Officer |
|
2010-10-07 |
4 |
AS |
$9.67 |
$676,900 |
I/I |
(70,000) |
0 |
|
- |
|
182 Records found
|
|
Page 2 of 8 |
|
|